{"id":"soc-4f-pcc","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspnea"}]},"_chembl":{"chemblId":"CHEMBL5975128","moleculeType":null,"molecularWeight":"680.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug blocks PAR-1, a G-protein coupled receptor activated by thrombin, which plays a key role in platelet activation and thrombosis. By antagonizing PAR-1, SOC 4F-PCC reduces pathological clot formation while potentially preserving hemostasis. This mechanism is distinct from conventional anticoagulants and antiplatelet agents.","oneSentence":"SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:35:04.269Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (Phase 3)"}]},"trialDetails":[{"nctId":"NCT05156983","phase":"PHASE3","title":"A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Coagulation Disorder","enrollment":328}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SOC 4F-PCC","genericName":"SOC 4F-PCC","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events. Used for Acute coronary syndrome (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}